Executive Director, Multimodal & Minimally Invasive Biomarker Strategy · Cancer Biomarker Development

Tue, 28 Apr 2026 15:09:38 GMT
Science

Cancer Biomarker Development · Boston, Massachusetts, United States of America · hybrid

As Executive Director, Multimodal & Minimally Invasive Biomarker Strategy, you will define enterprise strategy and drive portfolio impact by establishing a consistent and scalable approach to minimally invasive and multimodal biomarkers. You will partner with Translational Medicine to align biomarker strategies with development plans and influence key decisions, such as go/no-go, dose selection, and patient selection.

You will guide the development of ctDNA monitoring strategies that assess target engagement, depth and durability of response, and emergence of resistance, contributing to molecular response endpoints that complement or extend traditional radiographic endpoints. You will also articulate and defend biomarker strategies in governance discussions with senior leadership.

This role requires a leader who wants to move beyond individual biomarker strategies and build a more consistent and scalable approach that improves how decisions are made across the oncology portfolio. You will lead and develop a team of scientists and strategists across career levels, from early-career scientists to senior directors.

Key responsibilities include:

Defining enterprise strategy for minimally invasive and multimodal biomarkers

Building decision frameworks that guide when these approaches should and should not be used

Developing approaches that enable comparability, reuse, and learning across studies

Defining and tracking metrics that demonstrate value

Partnering with Translational Medicine to align biomarker strategies with development plans

Influencing key decisions, such as go/no-go, dose selection, and patient selection

Guiding the development of ctDNA monitoring strategies

Articulating and defending biomarker strategies in governance discussions

Leading and developing a team of scientists and strategists

Required qualifications include:

PhD, MD, or MD/PhD in molecular biology, cancer biology, genomics, or related scientific discipline

15+ years of progressive experience in oncology biomarker development with demonstrated advancement into senior leadership roles

Deep experience with ctDNA and other minimally invasive biomarker approaches

Proven ability to develop decision frameworks and establish when biomarker approaches should and should not be used

Demonstrated success connecting biomarker strategy to clinical development and influencing major development decisions at the portfolio level

Experience working in complex, matrixed environments and influencing across functions and senior leadership levels without direct authority

Track record of building and leading high-performing teams across multiple career levels

Experience developing approaches that enable reuse and learning across multiple programs

Proven ability to articulate and defend complex scientific strategies in governance discussions

Executive-level communication skills with ability to engage audiences from bench scientists to C-suite leadership and regulatory authorities

Experience managing strategic vendor relationships and ensuring technology investments support coherent platform approaches

Demonstrated ability to build systems that enable portfolio-level learning and continuous improvement

Preferred qualifications include:

Experience translating biomarkers into regulated diagnostics, such as companion diagnostics

Familiarity with diagnostic development and regulatory frameworks

Experience with multimodal data integration across tissue, blood, and imaging modalities

Experience with AI/ML applications and computational approaches in biomarker development

Broad experience across tumor types and therapeutic modalities

Experience developing molecular response endpoints that complement or extend traditional radiographic endpoints

External scientific visibility through high-impact publications or presentations at major conferences

Experience contributing to organizational or strategic transformation initiatives

Track record of establishing standardized, scalable approaches while maintaining appropriate program flexibility

Experience positioning organizations as preferred partners with leading diagnostic providers